Danazol – możliwości wykorzystania w leczeniu chorób hematologicznych

Arkadiusz Macheta, Agnieszka Szymczyk, Monika Podhorecka
In: Acta Haematologica Polonica · 2014 · vol. 45(2) , pp. 184–189 · doi:10.1016/j.achaem.2014.04.005 · W2064972182
Review OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-18 ⓘ

This review examines danazol's potential therapeutic applications in hematology, particularly for autoimmune disorders like immune thrombocytopenic purpura and autoimmune hemolytic anemia, and in neoplastic hematological conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol is an attenuated synthetic hormone with weak androgenic effects. It has unique properties similar to those of corticosteroids and has a structure related to testosterone and ethisterone. Danazol is widely used for endometriosis and in mammary gland dysplasia treatment. Among the others, it can be also a therapeutical option for patients with autoimmunological disorders, such as immune thrombocytopenic purpura and autoimmune hemolytic anemia. The attempts of danazol therapy in neoplastic hematological proliferations were also reported. In this article we present the literature review of options of danazol usage in hematology.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (40)

Source provenance

openalex
last seen: 2026-05-10T10:39:54.929377+00:00
License: CC0 · commercial use OK